Market Place
Sourcing Support
US FDA approves Iterum`s treatment for urinary infection
26 Oct 2024 //
REUTERS
FDA Concerns Over Iterum`s UTI Drug And Antimicrobial Resistance
06 Sep 2024 //
FIERCE BIOTECH
Iterum Announces Positive Topline Results from Phase 3 Trial of Oral Sulopenem
30 Jan 2024 //
PR NEWSWIRE
Iterum Therapeutics Reports Employment Inducement Grant
11 Jan 2023 //
GLOBENEWSWIRE
Iterum announces Issuance of Allowance for Patent Covering Oral Sulopenem
15 Dec 2022 //
GLOBENEWSWIRE
Iterum Therapeutics Reports 3Q 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Iterum Therapeutics Report Third Quarter 2022 Financial Results in November
03 Nov 2022 //
GLOBENEWSWIRE
Iterum Announces First Patient Dosed in REASSURE
20 Oct 2022 //
GLOBENEWSWIRE
Iterum Therapeutics to Present Data at IDWeek 2022
17 Oct 2022 //
GLOBENEWSWIRE
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering
19 Sep 2022 //
GLOBENEWSWIRE
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
01 Sep 2022 //
GLOBENEWSWIRE
Iterum Tx Announces Special Protocol Assessment (SPA) Agreement With the FDA
11 Jul 2022 //
GLOBENEWSWIRE
Iterum Tx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 Jul 2022 //
GLOBENEWSWIRE
Iterum Tx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14 Jun 2022 //
GLOBENEWSWIRE
Iterum Therapeutics Reports First Quarter 2022 Financial Results
13 May 2022 //
GLOBENEWSWIRE
Iterum Therapeutics Provides Regulatory Update
11 May 2022 //
GLOBENEWSWIRE
Iterum says FDA is in `alignment` on proposed new PhIII for rejected uUTI drug
11 May 2022 //
ENDPTS
Iterum Therapeutics Presented Data at the 32nd European Congress
25 Apr 2022 //
GLOBENEWSWIRE
Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
Iterum Tx to Report Q4 and Full Year 2021 Financial Results
21 Mar 2022 //
GLOBENEWSWIRE
Iterum Tx Granted 180-Day Extension by Nasdaq
10 Mar 2022 //
GLOBENEWSWIRE
Iterum Tx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08 Feb 2022 //
GLOBENEWSWIRE
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635
14 Dec 2021 //
GLOBENEWSWIRE
Former Iterum VP returns as medical lead to test UTI drug again
14 Dec 2021 //
FIERCEBIOTECH
Iterum Reports Q3 2021 Financial Results and Provides Business Update
12 Nov 2021 //
GLOBENEWSWIRE
FDA said no in July, so Iterum will test UTI antibiotic again
30 Sep 2021 //
FIERCEBIOTECH
Iterum Therapeutics Provides Update from FDA Type A Meeting Oral Sulopenem
28 Sep 2021 //
GLOBENEWSWIRE
Iterum Therapeutics Reports Second Quarter 2021 Financial Results
13 Aug 2021 //
GLOBENEWS WIRE
Iterum Therapeutics to Provide Business Update
06 Aug 2021 //
GLOBENEWSWIRE
Iterum hit with FDA complete response letter for oral UTI drug sulopenem
26 Jul 2021 //
PRESS RELEASE
Iterum hit with FDA complete response letter for oral UTI drug sulopenem
26 Jul 2021 //
PRESS RELEASE
Iterum Complete Response Letter from U.S.FDA for Oral Sulopenem
26 Jul 2021 //
GLOBENEWSWIRE
Iterum slumps as FDA finds deficiencies in its antibiotic NDA
06 Jul 2021 //
PHARMALETTER
Iterum shares hit as "deficiencies" stall FDA review of oral UTI drug sulopenem
02 Jul 2021 //
FIRSTWORDPHARMA
Iterum Therapeutics Provides Regulatory Update
01 Jul 2021 //
GLOBENEWSWIRE
Iterum Therapeutics Provides Update on NDA Review
27 May 2021 //
GLOBENEWSWIRE
Iterum Therapeutics Provides Update on NDA Review
27 May 2021 //
YAHOO
Iterum (ITRM) says FDA needs more time to review materials in support of NDA
09 Apr 2021 //
STREETINSIDER
Iterum Announces $35.0 Million Registered Direct Offering of Ordinary Shares
10 Feb 2021 //
GLOBENEWSWIRE
Iterum Therapeutics Announces Exercise of Underwriter’s Option
10 Feb 2021 //
GLOBENEWSWIRE
Iterum Announces Collaboration with EVERSANA to Support Oral Sulopenem
01 Feb 2021 //
EVERSANA
Iterum Announces U.S. FDA Filing Acceptance of NDA for Oral Sulopenem
25 Jan 2021 //
PRESS RELEASE
Iterum Therapeutics Announces Filing of US Patent Application Based on Favorable
07 Dec 2020 //
PRESS RELEASE
Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offering
23 Oct 2020 //
GLOBENEWSWIRE
Iterum Therapeutics to Present Data from Phase 3 Trials
19 Oct 2020 //
GLOBENEWSWIRE
Iterum Announces $5 M Registered Direct Offering Priced At-the-Market
30 Jun 2020 //
GLOBENEWSWIRE
Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial
29 Jun 2020 //
GLOBENEWSWIRE
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced
03 Jun 2020 //
GLOBENEWSWIRE
